BeyondAirInc . (NASDAQ: XAIR) is one of 127 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its competitors? We will compare BeyondAirInc . to related businesses based on the strength of its institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.
This table compares BeyondAirInc . and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BeyondAirInc . Competitors||-674.05%||-624.58%||-22.23%|
Risk & Volatility
BeyondAirInc . has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500. Comparatively, BeyondAirInc .’s competitors have a beta of 1.00, suggesting that their average stock price is 0% less volatile than the S&P 500.
Institutional & Insider Ownership
0.3% of BeyondAirInc . shares are owned by institutional investors. Comparatively, 51.1% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 15.2% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a summary of recent recommendations and price targets for BeyondAirInc . and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BeyondAirInc . Competitors||933||3162||5359||281||2.51|
As a group, “Surgical & medical instruments” companies have a potential upside of 22.19%. Given BeyondAirInc .’s competitors higher possible upside, analysts plainly believe BeyondAirInc . has less favorable growth aspects than its competitors.
Earnings and Valuation
This table compares BeyondAirInc . and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|BeyondAirInc .||$7.72 million||-$6.56 million||-5.79|
|BeyondAirInc . Competitors||$1.43 billion||$145.31 million||-9.95|
BeyondAirInc .’s competitors have higher revenue and earnings than BeyondAirInc .. BeyondAirInc . is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
BeyondAirInc . competitors beat BeyondAirInc . on 7 of the 10 factors compared.
About BeyondAirInc .
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.
Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with MarketBeat.com's FREE daily email newsletter.